Aeglea BioTherapeutics (AGLE) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares.
View AGLE analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year price targets for Aeglea BioTherapeutics' stock. Their AGLE share price forecasts range from $12.50 to $37.50. On average, they anticipate the company's share price to reach $24.38 in the next twelve months. This suggests a possible upside of 98.7% from the stock's current price.
View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts.

Aeglea BioTherapeutics' stock was trading at $11.2475 on January 1st, 2023. Since then, AGLE shares have increased by 9.1% and is now trading at $12.27.
View the best growth stocks for 2023 here.

Aeglea BioTherapeutics saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 61,600 shares, a decrease of 96.1% from the August 15th total of 1,570,000 shares. Based on an average daily volume of 256,400 shares, the short-interest ratio is presently 0.2 days. Currently, 1.5% of the company's shares are sold short.
View Aeglea BioTherapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AGLE earnings forecast.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($41.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.50) by $37.00. The biotechnology company had revenue of $0.69 million for the quarter. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%.

Aeglea BioTherapeutics's stock reverse split before market open on Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Aeglea BioTherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include VR Adviser LLC (9.70%), Affinity Asset Advisors LLC (7.49%), Driehaus Capital Management LLC (7.10%), Commodore Capital LP (4.45%), Goldman Sachs Group Inc. (0.85%) and BlackRock Inc. (0.81%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza.
View institutional ownership trends.

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGLE stock can currently be purchased for approximately $12.27.

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $49.69 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($71.00) on an earnings per share basis.

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.